Advanced Medicine In Brief
March 16, 2020
The world’s largest cell and gene CDMO, an exciting new TCR, and the global CAR-T picture… We examine what’s going on in advanced medicine
0 min read
February 2020
In February’s cover feature, find out what it takes to develop, safely deliver and commercialize a CAR T cell therapy with Kite Pharma. We ask what the Brexit transition period means for the pharma industry, and in particular, batch release; while Andrew Edwards argues that current market conditions aren’t suited to the development of antibiotics. In addition, find out how greater supply chain transparency will help address shortages, why so many drugs fail the final hurdle, and the benefits and dangers of human germline genome editing. We also sit down with Matthew Todd, Open Source Pharma founder.
Cost of a Cure
March 14, 2020
Gene therapies (including CAR-T) could add $45 billion to US healthcare costs over the next five years, CVS Health report finds
0 min read
Image of the Month: A Piercing Barb
March 11, 2020
Engineers from Rutgers used 4D printing to create tiny needles that mimic parasites with backward-facing barbs. The researchers hope this technology could replace hypodermic needles
0 min read
Failing Safely: Why Ending Some Programmes Early May Be a Recipe for Successes Later
February 27, 2020
With so much time and money invested into pre-clinical research and early phase clinical trials, why are compounds still failing at the final hurdle?
1 min read
Manufacture
Cell & Gene
Regulation & Standards
Business & Trends
Facilities & Equipment
Technology & Manufacturing
Hands Off the Goods
February 27, 2020
Aseptic filling is the final manufacturing step but it shouldn’t be an afterthought. It’s time to adopt closed, automated processes for the drugs of today and tomorrow.
1 min read
Point of Care, Point of Commercialization
February 26, 2020
UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house
1 min read
Rising to the ADC Challenge
February 25, 2020
The ADC market has continued to grow over the last decade – what advances should be embraced for true success?
1 min read
Sharing is Caring
February 25, 2020
Sitting down with… Matthew Todd, Chair of Drug Discovery at UCL and founder of the Open Source Pharma movement
1 min read
CAR T Cell Therapy: Redefining Quality
February 21, 2020
With CAR T cell therapy, quality takes on a whole new meaning. Bethany Dudek, Executive Director, Quality Head Europe at Kite, walks us through the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.
1 min read
A Matter of (Cellular) Integrity
February 20, 2020
A cell-free biologic could act as platform therapeutic for a variety of serious diseases.
1 min read
Greater Transparency; Fewer Shortages
February 19, 2020
Greater transparency in supply chains will help address shortages
1 min read
Where's the Off Switch?!
February 18, 2020
Researchers seek a way to inactivate CAR-T cells in case of adverse effects
1 min read
Antibiotic Apocalypse: Resistance is (Not) Futile
February 18, 2020
Threatening global economies, healthcare systems and human lives, the issue of antibiotic resistance is ever-present. But how much closer are we to resolving the problem?
1 min read
The Patient Is the Priority
February 17, 2020
As we announce a new Special Series of articles devoted to advanced medicine – and in light of public health crises and geopolitical changes – let’s not lose sight of what’s most important: the patient
1 min read
